Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 12 clinical trials
A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis

Phase 1 Part (Complete): Open-label, sequential dose escalation study of CPI-0610 in patients with previously treated Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative

acute leukemia
platelet count
myelodysplastic syndromes
myelodysplastic/myeloproliferative neoplasms
growth factor
  • 242 views
  • 04 Feb, 2021
  • 59 locations
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations

myelodysplastic/myeloproliferative neoplasm with FLT3 or CBL mutations. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping

growth factor
decitabine
colony stimulating factor
chemotherapy drugs
granulocyte colony stimulating factor
  • 0 views
  • 25 Jan, 2021
Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm

This phase II trial studies how well ruxolitinib phosphate and azacytidine work in treating patients with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacytidine, work in different …

direct bilirubin
mds/mpd
essential thrombocythemia
azacitidine
polycythemia
  • 65 views
  • 26 Jan, 2021
  • 1 location
Azacitidine Venetoclax and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia Chronic Myelomonocytic Leukemia or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

This phase I/II trial studies the side effects and best dose of gilteritinib and to see how well it works in combination with azacitidine and venetoclax in treating patients with FLT3-mutation positive acute myeloid leukemia, chronic myelomonocytic leukemia, or high-risk myelodysplastic syndrome/myeloproliferative neoplasm that has come back (recurrent) or has …

  • 8 views
  • 28 Mar, 2021
  • 1 location
Azacitidine Venetoclax and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

This phase I/II trial studies the best dose of venetoclax when given together with azacitidine and pevonedistat and to see how well it works in treating patients with newly diagnosed acute myeloid leukemia. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer …

spermicides
atypical chronic myeloid leukemia
chronic myeloid leukemia
azacitidine
blood transfusion
  • 40 views
  • 18 Mar, 2021
  • 1 location
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in …

chronic lymphocytic leukemia
solid tumor
idelalisib
dasatinib
pancreatic adenocarcinoma
  • 0 views
  • 27 Jan, 2021
  • 1 location
Early Diagnosis of Aspergillosis in Patients at High Risk of Fungal Infection Caused by Treatment for Hematologic Cancer or Other Disease

RATIONALE: Studying ways to diagnose fungal infections early may help doctors plan the best treatment. PURPOSE: This clinical trial is studying laboratory tests to see how well they find aspergillosis early in patients at high risk of fungal infection caused by treatment for hematologic cancer or other disease.

PCR test
fungal infection
hematologic malignancy
cancer
  • 52 views
  • 07 Nov, 2020
  • 1 location
Myeloproliferative Neoplasms (MPNs) Patient Registry

The mandate of this MPN registry is to collect clinical information, including molecular results, from consenting patients with a variety of MPNs at different time points during the course of their disease.

thrombocytosis
myelomonocytic leukemia
post essential thrombocythemia myelofibrosis
leukemia
ringed sideroblasts
  • 54 views
  • 08 Apr, 2021
  • 1 location
Study of MGUS Smoldering Myeloma Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

Blood cancers occur when the molecules that control normal cell growth are damaged. Many of these changes can be detected by directly examining parts of the cancer or cells in blood. Several alterations that occur repeatedly in certain types of blood cancers have already been identified, and these discoveries have …

lymphoma
multiple myeloma
chemotherapy regimen
alkylating agents
bone marrow procedure
  • 140 views
  • 24 Jan, 2021
  • 2 locations
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

hematologic malignancy
cancer
  • 643 views
  • 16 May, 2021
  • 147 locations